Prasugrel, a third generation thienopyridine and potent platelet inhibitor.

Abstract

Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.

• Authors: Paul A Gurbel, Udaya S Tantry
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 9 Issue 3 Pg. 324-36 (Mar 2008) ISSN: 1472-4472 [Print] England
• PMID: 18311669 (Publication Type: Journal Article, Review)

Chemical References

• Piperazines
• Platelet Aggregation Inhibitors
• Thiophenes
• Prasugrel Hydrochloride

Topics

• Animals
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Humans
• Patents as Topic
• Piperazines (adverse effects, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use)
• Platelet Aggregation Inhibitors (adverse effects, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use)
• Prasugrel Hydrochloride
• Structure-Activity Relationship
• Thiophenes (adverse effects, chemical synthesis, pharmacokinetics, pharmacology, therapeutic use)
• Thromboembolism (drug therapy)